Browse Studies — Arctuva

Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small p…

Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid Tumor+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT03739827

Phase 1

A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vi…

Refractory Solid TumorsRelapsed Solid TumorsRelapsed Neuroblastoma+3 more

Estimated

~$10 – $7,500

Theodore LaetschNCT06721689

Phase 1

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

Refractory Solid Tumors

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06006273

Phase 1

Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors

Subjects will undergo baseline evaluation and an assessment of extent of disease. Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-…

Advanced Refractory Solid TumorsSubjects Considered Likely to Respond to CB-03-10

Estimated

~$10 – $8,750

Cosmo Technologies LtdNCT03863145